TESARO Announces Participation at Four Investor Conferences

| Quelle: TESARO, Inc. TESARO, Inc.

WALTHAM, Mass., Aug. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor conferences. The four conferences are:

  • The Wells Fargo Global Healthcare Conference at the Westin Boston Waterfront in Boston on Wednesday, September 6. Tim Pearson, Executive Vice President and CFO of TESARO, is scheduled to present an overview of the Company’s business and development programs at 9:40 AM ET on September 6, and will also host meetings with investors.
     
  • The 12th Annual Citi Biotech Day at the Mandarin Oriental Hotel in Boston on Wednesday, September 6 and Thursday, September 7, 2017. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat from 10:00 to 10:50 AM ET on Thursday, September 7, and will also host meetings with investors.
     
  • The Baird 2017 Global Healthcare Conference at the InterContinental New York Barclay in New York City on Wednesday, September 6. Grant Bogle, Senior Vice President and Chief Commercial Officer of TESARO, is scheduled to participate in an analyst-led fireside chat from 9:40 to 10:10 AM ET on September 6, and will also host meetings with investors.
     
  • The Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology at the Lotte New York Palace in New York City on Thursday, September 28, 2017. Lonnie Moulder and Mary Lynne Hedley, Ph.D. will participate in an analyst-led fireside chat from 1:00 to 1:55 PM ET, and in meetings with investors.

Live webcasts of the presentations at the Wells Fargo, Citi, Baird and Leerink Partners conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.

About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.


            











    

        

        
Kontaktdaten